Últimos Artículos de Lancet Diabetes & Endocrinology
- [Correspondence] Declaration of Lisbon
- [Editorial] Stem-cell therapy for diabetes: the hope continues
- [Articles] Evolving epidemiological patterns of thyroid cancer and estimates of overdiagnosis in 2013–17 in 63 countries worldwide: a population-based study
- [Comment] The growing global burden of thyroid cancer overdiagnosis
- [Comment] Ultra-long-acting insulin: a new chapter in diabetes therapy?
- [Articles] Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1
- [Articles] Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study
- [Comment] Type 2 diabetes in familial hypercholesterolaemia: another look at traditional risk factors
- [Review] Osteopenia: a key target for fracture prevention
- [Review] Aberrant hormone receptors regulate a wide spectrum of endocrine tumors
- [Articles] Dysglycaemia screening and its prognostic impact in patients with coronary artery disease: experiences from the EUROASPIRE IV and V cohort studies
- [Comment] Dysglycaemia in cardiovascular disease: what's the best glycaemic risk predictor?
- [Corrections] Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50
- [Editorial] The unhealthy politics of health
- [Comment] Muscle matters: the effects of medically induced weight loss on skeletal muscle
- [Articles] Islet-after-kidney transplantation versus kidney alone in kidney transplant recipients with type 1 diabetes (KAIAK): a population-based target trial emulation in France
- [Articles] Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial
- [Articles] Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials
- [Comment] Sodium–glucose co-transporter type-2 inhibitors for hospitalised patients with COVID-19: safe but not protective
- [Comment] Islet transplantation in kidney transplant recipients with type 1 diabetes